Ionis Pharmaceuticals Inc (NASDAQ: IONS) is -6.66% lower on its value in year-to-date trading and has touched a low of $31.03 and a high of $52.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IONS stock was last observed hovering at around $33.17 in the last trading session, with the day’s loss setting it -0.54%.
Currently trading at $32.63, the stock is -1.47% and -6.65% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.23 million and changing -1.63% at the moment leaves the stock -19.63% off its SMA200. IONS registered -33.99% loss for a year compared to 6-month loss of -30.62%. The firm has a 50-day simple moving average (SMA 50) of $34.9806 and a 200-day simple moving average (SMA200) of $40.64125.
The stock witnessed a -4.31% gain in the last 1 month and extending the period to 3 months gives it a -15.11%, and is -2.07% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.53% over the week and 4.50% over the month.
Ionis Pharmaceuticals Inc (IONS) has around 927 employees, a market worth around $5.15B and $803.56M in sales. Profit margin for the company is -44.62%. Distance from 52-week low is 5.16% and -37.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-13.78%).
with sales reaching $140.97M over the same period.The EPS is expected to shrink by -36.11% this year, but quarterly earnings will post -21.33% year-over-year. Quarterly sales are estimated to shrink -56.62% in year-over-year returns.
518.0 institutions hold shares in Ionis Pharmaceuticals Inc (IONS), with institutional investors hold 103.89% of the company’s shares. The shares outstanding are 157.81M, and float is at 154.00M with Short Float at 6.65%. Institutions hold 103.01% of the Float.
The top institutional shareholder in the company is FMR LLC with over 21.89 million shares valued at $1.04 billion. The investor’s holdings represent 15.044 of the IONS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.85 million shares valued at $659.89 million to account for 9.5135 of the shares outstanding. The other top investors are T. ROWE PRICE INVESTMENT MANAGEMENT, INC. which holds 12.64 million shares representing 8.6848 and valued at over $602.41 million, while BLACKROCK INC. holds 7.0916 of the shares totaling 10.32 million with a market value of $491.9 million.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
The most recent transaction is an insider sale by O’NEIL PATRICK R., the company’s EVP CLO & General Counsel. SEC filings show that O’NEIL PATRICK R. sold 6,165 shares of the company’s common stock on Feb 04 ’25 at a price of $31.62 per share for a total of $0.19 million. Following the sale, the insider now owns 57452.0 shares.
Ionis Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 04 ’25 that Monia Brett P (Chief Executive Officer) sold a total of 38,843 shares of the company’s common stock. The trade occurred on Feb 04 ’25 and was made at $31.65 per share for $1.23 million. Following the transaction, the insider now directly holds 0.18 million shares of the IONS stock.
Still, SEC filings show that on Feb 04 ’25, Monia Brett P (Officer) Proposed Sale 40,003 shares at an average price of $32.13 for $1.29 million. The insider now directly holds shares of Ionis Pharmaceuticals Inc (IONS).
